Head-to-head evidence
PF-06946860 vs Visugromab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: GDF-15 · full Non-Small Cell Lung Cancer pipeline
PF-06946860
Developed by Pfizer
NCT04299048 · Phase 1 · completed
Every participant in this small study received the same drug with no placebo or control group, so the reported adverse-event and laboratory-abnormality rates cannot be attributed to the drug versus the underlying advanced cancer and cachexia; all patients had an adverse event and roughly 40% had a serious adverse event, including one death.
Visugromab
Developed by CatalYm GmbH
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2029 · NCT07098988 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: PF-06946860's landscape · Visugromab's landscape